Please login to Zacks.com or register to post a comment.
They're hand-picked from the list of Zacks Rank #1 Strong Buys. Our experts predict that their prices will jump the soonest.
Today, you can see them free.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| STAAR SURGIC | STAA | 10.98% |
| DTS INC | DTSI | 6.89% |
| ANIKA THERAP | ANIK | 6.04% |
| LUMOS NETWOR | LMOS | 5.70% |
| INSTEEL IND | IIIN | 5.28% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
This prompted analysts to raise their estimates for both 2011 and 2012, sending the stock to a Zacks #2 Rank (Buy).
Cyclical as She Goes
Timken manufactures bearings, alloy steel, and other related components. The company is very cyclical and highly dependent on the health of the overall economy.
So as you can imagine, shares pulled back considerably in late summer/early fall over fears that another recession in the U.S. was looming. Although recession fears have waned and the stock has rallied over the last few weeks, it is still well below its previous highs.
Third Quarter Results
Timken delivered strong results for the third quarter of 2011 on October 27. Earnings per share came in at $1.12, beating the Zacks Consensus Estimate by 4 cents. It was a stellar 53% increase over the same quarter in 2010. So how'd they get there?
First, revenues jumped 25% to $1.322 billion, also ahead of the Zacks Consensus Estimate, which was $1.279 billion. The Process Industries and Steel segments were particularly strong due in part to strong demand.
Secondly, margins expanded. Gross profit improved from 25.0% of net sales to 26.0%. And operating income expanded from 11.5% of net sales to 14.1% as the company leveraged its selling, general and administrative expenses.
Outlook
Management raised its guidance for the remainder of the year following better than expected Q3 results. The company now expects EPS between $4.45 and $4.55 on sales growth of 25-30%. This is up from previous guidance of $4.30-$4.50 per share.
This prompted analysts to revise their estimates higher for both 2011 and 2012, sending the stock to a Zacks #2 Rank (Buy).
The Zacks Consensus Estimate for 2011 is now $4.57, slightly above guidance. This corresponds with EPS growth of 55%. The 2012 consensus estimate is currently $5.19, representing 14% EPS growth.
As you can see in Timken's Price & Consensus chart, consensus estimates have been trending significantly higher over the last several months as the company has delivered some impressive results:
Dividend
On top of solid earnings growth, Timken pays a dividend that yields 1.9%. The company has raised it three times since early 2010, but it did cut it in half during the Great Recession.
As long as earnings can grow as projected, I'd expect to see more dividend hikes on the horizon.
Valuation
The recent pullback in the stock market has led to some compelling valuations, as long as a recession isn't right around the corner.
Shares trade at just 8.1x 12-month forward earnings, a significant discount to the industry average of 11.0x and its 10-year historical median of 12.6x.
Its PEG ratio is only 0.5 based on a 5-year EPS growth rate of 17.8%.
The Bottom Line
With rising earnings estimates, strong growth projections, a solid 1.9% dividend yield and very attractive valuation, Timken offers investors a lot of upside potential...as long as the economy continues to improve.
Todd Bunton is the Growth & Income Stock Strategist for Zacks Investment Research and Co-Editor of the Reitmeister Value Investor.
Get the full Snapshot Report on TKR - FREE